AUCTUS Capital exits PharmaLex to AmerisourceBergen

• AmerisourceBergen’s acquisition of PharmaLex will build out its pharmaceutical distribution and biopharma manufacturer services capabilities in Europe
• PharmaLex has a footprint in Europe and the US and a growing presence in other parts of the world
• The company is a provider of specialised services for the life sciences industry

AUCTUS Capital is to exit PharmaLex, a provider of specialised services for the life sciences industry. AmerisourceBergen has agreed to buy the company for €1.28 billion in cash. The deal is expected to complete in March 2023.

PharmaLex is a provider of specialised services for the life sciences industry headquartered in Frankfurt. The company has a footprint in Europe and the US and a growing presence in other parts of the world.

AUCTUS Capital is a German private equity firm based in Munich that has made over 350 investments since 2001. The total revenue of all its portfolio companies exceeded €2 billion in 2021. The firm looks to make 20 to 30 new transactions per year. It looks to invest in companies with a turnover between €10 to €150 million with an operating profit of at least €2 million. AUCTUS invests across the IT, healthcare, business services, consumer and industrial sectors.

AmerisourceBergen is a global healthcare solutions provider headquartered in Conshohocken, Pennsylvania with revenues over $200 billion.